It is our capability and our commitment that make us GRAIL

We are taking on one of the biggest challenges of our lifetime, combining science, technology, and clinical studies to reveal cancer at its beginnings.

To detect cancer early, when it can be cured.

Finding a better way

At GRAIL, we find purpose in our mission and call on our passion as we tackle one of the most important problems in the world. Each person at GRAIL plays a vital role in navigating the complexity of our endeavor, and we continuously collaborate because we believe the whole is greater than the sum of its parts. We know that we have the drive, tools, and expertise to not only reach our goals but to accomplish them for the sake of humanity.

 

“ There has to be a better way for us, as a country and a world, to fight cancer. ”
Jeff Huber

Read More


Board of Directors

Jay T. Flatley

Jay was appointed President and CEO of Illumina in 1999 and oversaw the company’s expansion into the whole genome sequencing area with the acquisition of Solexa in 2006, and more recently into diagnostics and consumer sequencing.  Under his leadership, Illumina has been named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World’s Smartest Company in 2014.

 Previously, Jay served as President and Chief Executive Officer of Molecular Dynamics. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. He helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer. Currently, he is an Advisory Board member for UC San Diego’s Moores Cancer Center, and a member of the Board of Directors at Coherent, Denali, and Illumina, Inc.

 Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.

Jeff Huber

Prior to Grail, Jeff worked at Google[x] at the intersection of life sciences and computation. Previously at Google, Jeff led development for Google Ads (2003-2011), Google Apps (2005-2010), and Google Maps (2011-2013).

Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff holds a bachelor’s degree in computer engineering from the University of Illinois and a master’s degree from Harvard University. He is a board member of Electronic Arts (EA) and The Exploratorium, and former board member of Illumina (ILMN; 2014-2016).

Richard Klausner, M.D.

Dr. Richard Klausner is founder and Director of Juno Therapeutics and Executive Chairman of Wisdo, a third generation internet company. He is the chairman of Mindstrong and a Director of AnchorDx. He currently Chairs the Grand Challenges in Cancer program of Cancer Research UK.

Rick is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. He is the former Executive Chairman of Audax Health. Previously, he has also served as managing partner of the Venture Capital firm, The Column Group, and was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. He also served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. Rick holds an M.D. from Duke Medical School.

Robert Nelsen

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than thirty companies, including fifteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); NextCODE Health;  and Everyday Learning Corporation.

 Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Denali Therapeutics, Sage Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

Bill Rastetter, Ph.D.

Bill focuses on making and growing investments in biotechnology. He serves as chairman for Neurocrine Biosciences and Fate Therapeutics. He also serves as the lead outside director for Cerulean, and on the board of directors of Regulus, as well as an advisor to Leerink Partners, a healthcare focused investment bank. Bill was a founder and the chairman of Receptos that sold to Celgene in August 2015. Additionally, Bill serves on the Board of Trustees for Caltech.

Bill led the “merger of equals” that formed Biogen Idec in 2003, and retired as executive chairman at the end of 2005. Bill joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as chairman and CEO. While at Idec, Bill was a co-inventor of Rituxan® that became the first monoclonal antibody approved by the U.S. FDA for cancer, and one of the world’s most valuable cancer therapies. Prior to Idec, he served in various capacities at Genentech. Previously, Bill held various faculty positions at MIT, won the award for “Excellence in the Teaching of Chemistry” at Harvard, and was named an Alfred P. Sloan Fellow. He is a graduate of the Massachusetts Institute of Technology and Harvard.

Scientific Advisory Board

Jose Baselga

José Baselga is the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weil Cornell Medical College. His long-standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 394 peer-reviewed publications to date. Prior to MSK, Dr. Baselga was the Chief of the Division of Hematology / Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.  He also was the Chairman of Medical Oncology and Founding Director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain.  Dr. Baselga is the President of the American Association of Cancer Research (AACR), a past President of the European Society for Medical Oncology, and a past member of the Board of Directors for the American Society of Clinical Oncology and AACR.  He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and a Fellow of the AACR Academy.   He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, and Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal Cancer Discovery.

Hal V. Barron

Hal V. Barron is one of the most respected clinician-scientists and successful drug developers in the biotechnology industry. Hal is Calico’s president of research and development. He was most recently executive vice president, head of global product development, and chief medical officer of Hoffmann-La Roche. There he was responsible for all the products in the combined portfolio of Roche and Genentech. Barron joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions of increasing responsibility and leadership within cardiovascular research and specialty therapeutics. In 2002 Barron was promoted to vice president of medical affairs. In 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.

Prior to joining Genentech, Barron received his Bachelor of Science in physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California, San Francisco. Barron’s academic positions include associate adjunct professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Don Berry

Donald Berry is Professor and founding chair of the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. Dr. Berry received a Ph.D. in statistics from Yale University and he previously served on the faculties of the University of Minnesota and Duke University. He has held endowed faculty positions at Duke University and at M.D. Anderson. He has designed and supervised the conduct of many large clinical trials. A principal focus of his research is the use of biomarkers in cancer and other diseases for learning which patients benefit from which therapies, based on genomics and phenotype. In particular, he has designed and is a co-PI of I-SPY 2 www.ispy2.org and GBM AGILE nbdabiomarkers.org/gbm-agile, Bayesian adaptive platform clinical trials in high-risk early breast cancer and glioblastoma multiforme, respectively, whose goals are matching experimental therapies with patient subsets defined by tumor molecular characteristics. Through Berry Consultants, LLC he has designed many innovative clinical trials in all therapeutic areas for pharmaceutical and medical device companies and for international consortia. Dr. Berry is the author of books on statistical methodology and over 400 published articles. He serves on the PDQ Screening and Prevention Board of the National Cancer Institute for which he received the National Institutes of Health Award of Merit in 2010. In 2014 he was named a Thomson Reuters Highly Cited Researcher in Clinical Medicine and listed as one of The World’s Most Influential Scientific Minds in ScienceWatch.com. Dr. Berry has been the principal investigator for numerous research grants from the National Institutes of Health and the National Science Foundation. He is a Fellow of the American Statistical Association and the Institute of Mathematical Statistics.

Timothy R. Church

Timothy Church, Ph.D., is a professor in the Division of Environmental Health Sciences in the School of Public Health. His expertise is in cancer screening, colorectal cancer, medical device evaluation, biostatistics, epidemiologic methods, and clinical trial design. Dr. Church is currently leading multiple trials and studies regarding colorectal, prostate, lung, and ovarian cancer, and has recently established a registry for Parkinson’s Disease research. His primary research interests include clinical trials and epidemiological studies related to screening for and prevention of multiple cancers, as well as the development of biostatistical and epidemiologic methods. He teaches Occupational and Environmental Epidemiology and a doctoral seminar on causal inference.

Jeff Dean

Jeff Dean joined Google in 1999 and is currently a Google Senior Fellow in Google’s Research Group, where he leads the Google Brain team, Google’s deep learning research team in Mountain View, working on systems for speech recognition, computer vision, language understanding, and various predictive tasks. He has co-designed / implemented five generations of Google’s crawling, indexing, and query serving systems, and co-designed / implemented major pieces of Google’s initial advertising and AdSense for Content systems. He is also a co­designer and co­implementor of Google’s distributed computing infrastructure, including the MapReduce, BigTable and Spanner systems, protocol buffers, LevelDB, and TensorFlow, a popular open­-source system for machine learning.

Dean received a Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the Mark Weiser Award and the ACM­-Infosys Foundation Award in the Computing Sciences.

Brian Druker

Brian Druker M.D., is Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, OHSU, and an Investigator of the Howard Hughes Medical Institute. After training in oncology at Harvard’s Dana-Farber Cancer Institute, Dr. Druker returned to the lab to study the regulation of the growth of cancer cells and its application to cancer therapies. His work was instrumental in the development of Gleevec, a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker planned and led the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML, gastrointestinal stromal tumors and eight other tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the Kettering Prize from General Motors Cancer Research Foundation, the 2009 Lasker-DeBakey Award for Clinical Medical Research and the Japan Prize in Healthcare and Medical Technology. He was elected to the National Academy of Medicine in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

Sanjiv Sam Gambhir

Dr. Gambhir is the Virginia & D.K. Ludwig Professor of Cancer Research, Chairman of Radiology at Stanford University School of Medicine, and heads the Canary Center at Stanford for Cancer Early Detection. He received his medical and doctorate degrees from the University of California, Los Angeles, Medical Scientist Training Program. He has more than 570 publications in the field and more than 40 patents pending or granted. Dr. Gambhir is an internationally recognized researcher in molecular imaging with over $90 million of NIH funding as the Principal Investigator. His lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies. He was elected to the National Academy of Medicine in 2008 and to the Academy of Inventors in 2015.

Richard Klausner

Richard (Rick) Klausner joined Illumina as Senior Vice President and Chief Medical Officer in September 2013. He is also part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning, and operations.

 Prior to joining Illumina, Klausner was managing partner of the venture capital firm, The Column Group. Previously, he held roles as Executive Director for Global Health at the Bill and Melinda Gates Foundation and as the eleventh director of the National Cancer Institute between 1995 and 2001. He has served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. He also has been Chairman of the National Science Education Standards Projects of the National Academy of Sciences.

 Klausner currently chairs the International Advisory Board for Samsung, is the Chairman of Audax Health, and previously chaired the Strategic Oversight Council of Sanofi. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Klausner holds an M.D. from Duke Medical School.

Mostafa Ronaghi

Mostafa Ronaghi, Ph.D., joined Illumina in August 2008. As Senior Vice President and Chief Technology Officer, he is responsible for leading internal research and the Illumina accelerator program. Ronaghi is an experienced entrepreneur and was involved in the start-up of four life sciences companies. In 2007, Ronaghi co-founded Avantome, a privately held sequencing company (acquired by Illumina in 2008). Before this, he co-founded NextBio, a search engine for life science data (acquired by Illumina in 2013). In 2001, Ronaghi co-founded ParAllele Bioscience, which was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997, he co-founded Pyrosequencing AB, which was renamed to Biotage in 2003, and led the company to a successful initial public offering in June 2000 on the Stockholm Stock Exchange.

 Ronaghi was a principal investigator at Stanford University from 2002­ until 2008 and focused on the development of novel tools for molecular diagnostic applications. He serves on the board of directors of BaseHealth and Clear Labs.

 Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 30 patents and has written more than 70 peer-reviewed publications.

Sir Michael Stratton

Mike Stratton is Director of the Wellcome Trust Sanger Institute. His primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. He mapped and identified the major high risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate risk breast cancer and other cancer susceptibility genes.

In 2000 he initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute which conducts systematic genome­-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes.

He is a Fellow of the Royal Society (FRS) and was Knighted by the Queen in 2013.

Charles Swanton

Charles completed his MD/PhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Charles was appointed Cancer Research UK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the London Research Institute in 2008. He combines his laboratory research with clinical duties focused on biological mechanisms of cancer drug resistance. Charles was made Fellow of the Royal College of Physicians in April 2011 and Chair in Personalized Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011. Charles is the Chief Investigator of the CR-UK TRACERx lung cancer evolution study and is director of the CR-UK/UCL Lung Cancer Centre of Excellence. Charles was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013 and appointed Fellow of the European Academy of Cancer Sciences in 2013.

Karen Vousden

Karen is the Chief Scientist of Cancer Research UK, responsible for overseeing Cancer Research UK’s scientific research. She also leads a research group focused on understanding the regulation and functions of the p53 tumour suppressor protein, with an increasing emphasis on how changes in metabolism can influence cancer development. Her work has led to several possible clinical applications, including the development of small molecule activators of p53 that prevent the proteolytic degradation of the protein, and the potential of amino acid limited diets to augment standard chemotherapeutic approaches to treatment.

 Karen received her Ph.D. in Genetics from the University of London, followed by postdoctoral fellowships with Chris Marshall at the Institute of Cancer Research in London and Douglas Lowy at the National Cancer Institute in the USA. She has been elected as a Fellow of the Royal Society, the Royal Society of Edinburgh, EMBO, the Academy of Medical Sciences, the European Academy of Sciences, the American Association for the Advancement of Science, and the American Academy for Arts & Sciences. She received honorary DScs from the Universities of London and Strathclyde.

Investors

Contact Us

1525 O'Brien Drive
Menlo Park, CA 94025

Contact Public Relations

Contact Business Development